MedicineBiology

Targeting the Stromal-Immune Barrier: A Novel Strategy to Overcome Resistance to CLDN18.2/CD3 Bispecific T-Cell Engager Therapy in Pancreatic Cancer.

Shiqian Liu, M. Felsenstein, Shaokun Liu, Igor M. Sauer, Muhammad-Imtiaz Ashraf

2026.1.1CANCER LETTERS

DOI: 10.1016/j.canlet.2026.218248

Abstract

Abstract is not available.

Citation format

LIU, Shiqian, et al. Targeting the stromal-immune barrier: A novel strategy to overcome resistance to CLDN18.2/CD3 bispecific t-cell engager therapy in pancreatic cancer. CANCER LETTERS, 2026, 639: 218248.